Amine Kamen

Canada Research Chair in Bioprocessing of Viral Vectors and Vaccines

Tier 1 - 2017-11-01
Renewed: 2021-10-01
McGill University
Natural Sciences and Engineering Research Council


Research involves

Uncovering interactions between cells and viruses, and engineering cell cultures, to speed up the development and production of viral vaccines.

Research relevance

This research will support the manufacture and commercialization of safe, potent, cost-effective vaccines.

Research summary

During the COVID-19 pandemic, viral vector vaccines were a significant part of the global response—and they had to be developed, processed and delivered swiftly. Dr. Amine Kamen’s past vaccine research contributed to the knowledge and capacity-building that were ultimately involved in making this possible. Now, as Canada Research Chair in Bioprocessing of Viral Vectors and Vaccines, he is designing advanced manufacturing processes for safe, efficacious and cost-effective vaccines and delivery systems for live gene editing.

To support the delivery of high-value medicines in response to emerging infectious diseases, Kamen and his research team are working on an approach that integrates the genome-scale redesign of viral and cellular biological platforms, continuous process acceleration and intensification, and process analytical technologies and data sciences. They are also collaborating with industrial and institutional partners to help commercialize high-value, viral-based products, providing training to the Canadian biomanufacturing industry, and building sustained capacity in advanced vaccine manufacturing.